[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.54.109. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 297
Citations 0
Comment & Response
October 14, 2013

The Inferior Vena Cava Filter

Author Affiliations
  • 1Hofstra–North Shore LIJ School of Medicine, Monter Cancer Center of North Shore–LIJ Health Systems, Lake Success, New York
JAMA Intern Med. 2013;173(18):1754. doi:10.1001/jamainternmed.2013.8762

To the Editor The article by Prasad and colleagues1 reports that there has only been 1 randomized clinical trial (RCT) of the inferior vena cava (IVC) filter—the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) study.2 An additional RCT evaluating IVC filters in patients with cancer has been reported.3 Recognition of this RCT is of particular importance because it studied patients with cancer, who as a group are 6 times as likely to develop venous thromboses compared with the general population. Nearly 14 million Americans are living with cancer,4 and with the baby boom generation aging and an increasing life expectancy, the number of patients with cancer is expected to exceed 18 million by 2022.4

First Page Preview View Large
First page PDF preview
First page PDF preview
×